摘要
目的:评价南京地区医院调脂药的应用情况及趋势。方法:对南京地区31家医院2008-2011年调脂药的应用品种、销售金额及用药频度(DDDs)进行统计、分析。结果:该地区医院调脂药的销售金额逐年增加,2008-2010年销售金额排序列前3位的分别是阿托伐他汀钙、辛伐他汀、血脂康,2011年为阿托伐他汀钙、瑞舒伐他汀、辛伐他汀;2008年DDDs排序列前3位的分别是辛伐他汀、血脂康、阿托伐他汀钙,2009-2011年为阿托伐他汀钙、辛伐他汀、血脂康。结论:高效、低毒的他汀类药已成为降脂治疗的首选用药,更易被临床认可,是今后调脂药的发展方向。新型调脂药的上市为临床血脂异常的防治提供了更多的选择空间,市场前景看好。
OBJECTIVE： To evaluate the status quo and tendency of the utilization of fat-modulation drugs in Nanjing area. METHODS： The utilization of fat-modulating drugs in 31 hospitals of Nanjing area from 2008 to 2011 was analyzed statistically in terms of drug category, consumption sum and DDDs, etc. RESULTS： The consumption sum of fat-modulating drugs in Nanjing in- creased year by year. Atorvastatin, simvastatin and Xuezhikang ranked the top 3 in the list of consumption sum during 2008 -- 2010; atorvastatin, rosuvastatin and simvastatin ranked the top 3 in the list of consumption sum in 2011. Simvastatin, Xuezhikang and atorvastatin ranked the top 3 in the list of DDDs in 2008; and atorvastatin, simvastatin and Xuezhikang ranked the top 3 dur- ing 2009--2011. CONCLUSION： Statins is the dominant kind of fat-modulation drugs with high efficiency and low toxicity, which is more likely to be clinically recognized and represents the development direction of fat-modulation drugs. Novel fat-modulation drugs provide more choices for clinical prevention of abnormal blood lipid, and the market foreground is vastitude.
出处
《中国药房》
CAS
CSCD
2012年第38期3560-3563,共4页
China Pharmacy
关键词
调脂药
销售金额
用药频度
南京地区
Fat-modulation drugs
Consumption sum
DDDs
Nanjing area
